LXRX

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Lexicon Pharmaceuticals Inc

NASDAQ | LXRX

1.38

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 31, 2025)

$501.49M

Market Cap

-

P/E Ratio

-0.32

EPS

$1.66

52 Week High

$0.28

52 Week Low

HEALTHCARE

Sector

LXRX Chart

Recent Chart
Price Action

LXRX Technicals

Tags:

LXRX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $30M
Total Revenue $31M
Cost Of Revenue $616K
Costof Goods And Services Sold $616K
Operating Income -$197M
Selling General And Administrative $143M
Research And Development $84M
Operating Expenses $228M
Investment Income Net -
Net Interest Income -$3.3M
Interest Income $12M
Interest Expense $16M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $534K
Income Before Tax -$200M
Income Tax Expense -$200M
Interest And Debt Expense -
Net Income From Continuing Operations -$200M
Comprehensive Income Net Of Tax -
Ebit -$185M
Ebitda -$184M
Net Income -$200M

Revenue & Profitability

Earnings Performance

LXRX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $298M
Total Current Assets $246M
Cash And Cash Equivalents At Carrying Value $67M
Cash And Short Term Investments $67M
Inventory $231K
Current Net Receivables $3.5M
Total Non Current Assets $52M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill $45M
Investments -
Long Term Investments -
Short Term Investments $171M
Other Current Assets $4.5M
Other Non Current Assets -
Total Liabilities $152M
Total Current Liabilities $45M
Current Accounts Payable $15M
Deferred Revenue -
Current Debt -
Short Term Debt $1.2M
Total Non Current Liabilities $107M
Capital Lease Obligations $8.1M
Long Term Debt $100M
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $108M
Other Current Liabilities $29M
Other Non Current Liabilities -
Total Shareholder Equity $146M
Treasury Stock -
Retained Earnings -$2B
Common Stock $363K
Common Stock Shares Outstanding $320M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$179M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $534K
Capital Expenditures $1M
Change In Receivables -
Change In Inventory $150K
Profit Loss -
Cashflow From Investment -$15M
Cashflow From Financing $238M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -$1.7M
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$200M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $30M
Total Revenue $31M
Cost Of Revenue $616K
Costof Goods And Services Sold $616K
Operating Income -$197M
Selling General And Administrative $143M
Research And Development $84M
Operating Expenses $228M
Investment Income Net -
Net Interest Income -$3.3M
Interest Income $12M
Interest Expense $16M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $534K
Income Before Tax -$200M
Income Tax Expense -$200M
Interest And Debt Expense -
Net Income From Continuing Operations -$200M
Comprehensive Income Net Of Tax -
Ebit -$185M
Ebitda -$184M
Net Income -$200M

LXRX News

LXRX Profile

Lexicon Pharmaceuticals Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Lexicon Pharmaceuticals, Inc. (LXRX) is a biopharmaceutical company based in The Woodlands, Texas, specializing in the discovery, development, and commercialization of innovative therapies for metabolic and neuroendocrine disorders. Utilizing its proprietary gene-targeting technologies, Lexicon is advancing a robust pipeline of novel treatments aimed at addressing significant unmet medical needs in these therapeutic areas. With a strong leadership team committed to scientific excellence, the company is strategically positioned to improve patient outcomes while driving sustainable growth within the evolving healthcare landscape.

EPWK
+29.15%
$0.08
YDKG
+21.59%
$0.05
VHAI
-17.50%
$0.00
WTO
+6.92%
$0.04
HKD
+74.55%
$2.95
MSAI
+18.18%
$1.56
INTS
-44.68%
$0.73
NVDA
-0.19%
$202.49
AMZN
+9.58%
$244.22
BENF
+48.24%
$0.82
PFE
+1.48%
$24.65
GETY
-6.46%
$1.88
ASST
+9.91%
$1.33
DVLT
-19.44%
$2.02
ONDS
+2.38%
$6.44
BYND
+0.30%
$1.65
BURU
+0.26%
$0.33
BTG
-9.85%
$4.38
PLUG
+1.50%
$2.69
NOK
-3.08%
$6.91
MSPR
-30.29%
$0.22
T
+0.28%
$24.75
CTM
+13.59%
$1.17
DNN
-1.55%
$3.17
AAPL
-0.37%
$270.37
QS
+16.78%
$18.44
TSLA
+3.74%
$456.56
INTC
-0.42%
$39.99
BITF
-2.21%
$3.97
ACHR
+2.37%
$11.22
AZI
+3.38%
$0.09
RIG
-1.79%
$3.84
F
+0.53%
$13.13
NWL
-27.96%
$3.40
AXDX
-61.36%
$0.03
RGTI
+4.11%
$44.27
SOFI
+2.23%
$29.68
GPUS
-7.48%
$0.40
ADTX
-12.64%
$0.05
TGE
-53.70%
$0.77
RANI
+51.72%
$2.20
LAZR
-45.02%
$1.15
CJET
-9.39%
$0.04
META
-2.71%
$648.35
PLTR
+3.04%
$200.47
VZ
+2.00%
$39.74
CAN
+15.32%
$1.43
NIO
+3.42%
$7.25
ADAP
-15.14%
$0.05
CMG
-2.58%
$31.69
LUMN
-0.58%
$10.28
WULF
+4.58%
$15.50
MNOV
+39.49%
$1.66
KVUE
+0.91%
$14.37
VALE
+1.68%
$12.09
SNAP
+2.63%
$7.80
QUBT
+11.62%
$16.71
CCL
+1.76%
$28.83
RIVN
+4.46%
$13.57
AAL
+2.73%
$13.13
CIFR
-2.20%
$18.64
WBD
+3.83%
$22.45
JOBY
+4.77%
$17.34
RXRX
-2.30%
$5.52
GRAB
+0.50%
$6.01
CLF
+1.38%
$12.43
TLRY
+3.87%
$1.34
RMBL
+60.50%
$3.21
BAC
+0.79%
$53.45
GOOGL
-0.10%
$281.19
AMCR
+0.63%
$7.90
ADD
-25.47%
$0.05
ABEV
+0.43%
$2.31
QBTS
+2.63%
$37.06
ETHD
-10.66%
$3.77
BBD
-0.29%
$3.38
CABA
+46.15%
$3.61
SRM
+53.27%
$10.30
AMD
+0.50%
$256.12
MSFT
-1.51%
$517.80
LAES
+7.69%
$7.42
HPE
+0.04%
$24.42
MARA
+2.87%
$18.27
RIOT
-6.21%
$19.78
KDLY
+8.92%
$0.92
NAKA
+8.92%
$0.92
BTBT
+3.38%
$3.66
DFSC
+20.68%
$5.25
APLD
+2.09%
$34.65
KHC
+0.61%
$24.73
FI
+2.30%
$66.69
GOOG
-0.02%
$281.82
MRVL
+5.83%
$93.74
WLGS
-5.57%
$0.04
SOUN
+4.44%
$17.62
IXHL
-6.56%
$0.37
FUBO
+3.27%
$3.78
NVTS
+7.16%
$13.46
ETWO
0.00%
$3.30
DXCM
-14.63%
$58.22
EPWK
+29.15%
$0.08
YDKG
+21.59%
$0.05
VHAI
-17.50%
$0.00
WTO
+6.92%
$0.04
HKD
+74.55%
$2.95
MSAI
+18.18%
$1.56
INTS
-44.68%
$0.73
NVDA
-0.19%
$202.49
AMZN
+9.58%
$244.22
BENF
+48.24%
$0.82
PFE
+1.48%
$24.65
GETY
-6.46%
$1.88
ASST
+9.91%
$1.33
DVLT
-19.44%
$2.02
ONDS
+2.38%
$6.44
BYND
+0.30%
$1.65
BURU
+0.26%
$0.33
BTG
-9.85%
$4.38
PLUG
+1.50%
$2.69
NOK
-3.08%
$6.91
MSPR
-30.29%
$0.22
T
+0.28%
$24.75
CTM
+13.59%
$1.17
DNN
-1.55%
$3.17
AAPL
-0.37%
$270.37
QS
+16.78%
$18.44
TSLA
+3.74%
$456.56
INTC
-0.42%
$39.99
BITF
-2.21%
$3.97
ACHR
+2.37%
$11.22
AZI
+3.38%
$0.09
RIG
-1.79%
$3.84
F
+0.53%
$13.13
NWL
-27.96%
$3.40
AXDX
-61.36%
$0.03
RGTI
+4.11%
$44.27
SOFI
+2.23%
$29.68
GPUS
-7.48%
$0.40
ADTX
-12.64%
$0.05
TGE
-53.70%
$0.77
RANI
+51.72%
$2.20
LAZR
-45.02%
$1.15
CJET
-9.39%
$0.04
META
-2.71%
$648.35
PLTR
+3.04%
$200.47
VZ
+2.00%
$39.74
CAN
+15.32%
$1.43
NIO
+3.42%
$7.25
ADAP
-15.14%
$0.05
CMG
-2.58%
$31.69
LUMN
-0.58%
$10.28
WULF
+4.58%
$15.50
MNOV
+39.49%
$1.66
KVUE
+0.91%
$14.37
VALE
+1.68%
$12.09
SNAP
+2.63%
$7.80
QUBT
+11.62%
$16.71
CCL
+1.76%
$28.83
RIVN
+4.46%
$13.57
AAL
+2.73%
$13.13
CIFR
-2.20%
$18.64
WBD
+3.83%
$22.45
JOBY
+4.77%
$17.34
RXRX
-2.30%
$5.52
GRAB
+0.50%
$6.01
CLF
+1.38%
$12.43
TLRY
+3.87%
$1.34
RMBL
+60.50%
$3.21
BAC
+0.79%
$53.45
GOOGL
-0.10%
$281.19
AMCR
+0.63%
$7.90
ADD
-25.47%
$0.05
ABEV
+0.43%
$2.31
QBTS
+2.63%
$37.06
ETHD
-10.66%
$3.77
BBD
-0.29%
$3.38
CABA
+46.15%
$3.61
SRM
+53.27%
$10.30
AMD
+0.50%
$256.12
MSFT
-1.51%
$517.80
LAES
+7.69%
$7.42
HPE
+0.04%
$24.42
MARA
+2.87%
$18.27
RIOT
-6.21%
$19.78
KDLY
+8.92%
$0.92
NAKA
+8.92%
$0.92
BTBT
+3.38%
$3.66
DFSC
+20.68%
$5.25
APLD
+2.09%
$34.65
KHC
+0.61%
$24.73
FI
+2.30%
$66.69
GOOG
-0.02%
$281.82
MRVL
+5.83%
$93.74
WLGS
-5.57%
$0.04
SOUN
+4.44%
$17.62
IXHL
-6.56%
$0.37
FUBO
+3.27%
$3.78
NVTS
+7.16%
$13.46
ETWO
0.00%
$3.30
DXCM
-14.63%
$58.22
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.